Premium
Resveratrol attenuates Nitrosodiethylamine‐induced liver injury in anti‐inflammatory manner via regulating cyclooxygenase‐2
Author(s) -
Mukherjee Devoshree,
Ahmad Riaz
Publication year - 2018
Publication title -
journal of food biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.507
H-Index - 47
eISSN - 1745-4514
pISSN - 0145-8884
DOI - 10.1111/jfbc.12594
Subject(s) - resveratrol , hepatoprotection , liver injury , pharmacology , superoxide dismutase , alanine transaminase , aspartate transaminase , phytoalexin , chemistry , alkaline phosphatase , biochemistry , glycogen , antioxidant , medicine , enzyme , glutathione
Resveratrol is a polyphenolic phytoalexin with numerous health benefits including fat reducing ability as well as anti‐proliferative and pro‐apoptotic properties. It is found in fruits such as raspberry, strawberry, and grapes. Considering nutritional importance of Resveratrol, this study was undertaken to investigate its hepatoprotective effect against Nitrosodiethylamine (NDEA)‐induced liver injury in rats. Resveratrol was administered to NDEA‐intoxicated rats for 2 weeks. Hepato‐somatic Index (HSI), Aspartate Transaminase (AST), Alanine Transaminase (ALT), Alkaline Phosphatase (ALP), Lipid peroxides (LPO), Superoxide Dismutase (SOD), glycogen, and Na + /K + , Ca 2+ , Mg 2+ ATPase activities were determined. Alteration in the liver anatomy was monitored by Haematoxylin and Eosin and Masson’s Trichrome stainings. Cycloxygenase‐2 (COX‐2) activity was assessed by Immunohistochemistry and Western blotting. Resveratrol restitutes the NDEA‐induced decline in HSI, glycogen, SOD, ATPases, and coincidental increase in AST, ALT, ALP, and LPO. Resveratrol refurbishes architectural changes, reduces collagen amassing and COX‐2 positive cells in the liver. This study reveals that Resveratrol offers hepatoprotection against NDEA‐induced injury through its anti‐inflammatory action and declining COX‐2 expression. Practical applications Despite various documented roles of Resveratrol, there is still a paucity of literature supporting its hepatoprotective role. The growing prevalence of liver diseases has witnessed a surge of interest in medicinally important botanicals wherein hepatoprotective active ingredients can be identified. Although herbal medication is preferred over synthetic pharmaceuticals because of their inherent efficacy and negligible side‐effects, identification and mode of action of active ingredients requires compatible attention. This study is the first that reveals anti‐inflammatory potential of Resveratrol, exerted via declining COX‐2 that offers hepatoprotection against NDEA‐induced liver fibrosis. These findings suggest Resveratrol as a potential anti‐fibrotic agent and the COX‐2 as a prospective target for drug discovery.